Development of a first ‐in‐class unimolecular dual GIP/GLP‐2 analogue, GL‐0001, for the treatment of bone fragility
This article is protected by copyright. All rights reserved. (Source: Journal of Bone and Mineral Research)
Source: Journal of Bone and Mineral Research - February 28, 2023 Category: Orthopaedics Authors: Benoit Gobron,
Malory Couchot,
Nigel Irwin,
Erick Legrand,
B éatrice Bouvard,
Guillaume Mabilleau Tags: Research Article Source Type: research
The nanoformula of zoledronic acid and calcium carbonate targets osteoclasts and reverses osteoporosis
Biomaterials. 2023 Feb 17;296:122059. doi: 10.1016/j.biomaterials.2023.122059. Online ahead of print.ABSTRACTOsteoporosis is known as an imbalance in bone catabolism and anabolism. Overactive bone resorption causes bone mass loss and increased incidence of fragility fractures. Antiresorptive drugs are widely used for osteoporosis treatment, and their inhibitory effects on osteoclasts (OCs) have been well established. However, due to the lack of selectivity, their off-target and side effects often bring suffering to patients. Herein, an OCs' microenvironment-responsive nanoplatform HA-MC/CaCO3/ZOL@PBAE-SA (HMCZP) is develop...
Source: Biomaterials - February 27, 2023 Category: Materials Science Authors: Fei Jia Lifo Ruan Chuanchao Du Yu Liu Xiaomeng Cai Rui Dou Jiayu Zhang Xiaoguang Liu Jun Chen Xingcai Zhang Zhifang Chai Yi Hu Source Type: research
Zoledronic acid and denosumab for periprosthetic bone mineral density loss after joint arthroplasty: a systematic review and meta-analysis of randomized controlled trials
ConclusionIn the current analysis with evidence on the efficacy and safety of ZA and denosumab, the authors recommend the use of ZA or denosumab treatment for periprosthetic bone mineral density loss.Systematic review registration: PROSPERO registration number: CRD42022369273 (Source: Archives of Orthopaedic and Trauma Surgery)
Source: Archives of Orthopaedic and Trauma Surgery - February 25, 2023 Category: Orthopaedics Source Type: research
Zoledronic acid and denosumab for periprosthetic bone mineral density loss after joint arthroplasty: a systematic review and meta-analysis of randomized controlled trials
ConclusionIn the current analysis with evidence on the efficacy and safety of ZA and denosumab, the authors recommend the use of ZA or denosumab treatment for periprosthetic bone mineral density loss.Systematic review registration: PROSPERO registration number: CRD42022369273 (Source: Archives of Osteoporosis)
Source: Archives of Osteoporosis - February 25, 2023 Category: Orthopaedics Source Type: research
Real-World Management of Patients With Osteoporosis at Very High Risk of Fracture
In this study, we examined the prevalence of patients at very high risk of fracture and evaluated real-world treatment practices for these patients.METHODS: This retrospective observational cohort study used real-world data linked to commercial and Medicare medical claims from Symphony Health PatientSource. Patients 50 years and older with osteoporosis (determined by the presence of a diagnosis code) and at very high risk of fracture according to the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) (AACE/ACE) 2020 guidelines between January 1, 2018, and December 31, 2018,...
Source: The Journal of the American Academy of Orthopaedic Surgeons - February 15, 2023 Category: Orthopaedics Authors: Benjamin W Diffenderfer Yamei Wang Leny Pearman Nick Pyrih Setareh A Williams Source Type: research
